No retraction, correction or concern found when last checked on Oct 23, 2026.

Antiviral Lead Compounds from Marine Sponges

Sunil Sagar, Mandeep Kaur, Kenneth P. Minneman

Marine Drugs · 2010 · Review · CC BY

Abstract

Marine sponges are currently one of the richest sources of pharmacologically active compounds found in the marine environment. These bioactive molecules are often secondary metabolites, whose main function is to enable and/or modulate cellular communication and defense. They are usually produced by functional enzyme clusters in sponges and/or their associated symbiotic microorganisms. Natural product lead compounds from sponges have often been found to be promising pharmaceutical agents. Several of them have successfully been approved as antiviral agents for clinical use or have been advanced to the late stages of clinical trials. Most of these drugs are used for the treatment of human immunodeficiency virus (HIV) and herpes simplex virus (HSV). The most important antiviral lead of marine origin reported thus far is nucleoside Ara-A (vidarabine) isolated from sponge Tethya crypta. It inhibits viral DNA polymerase and DNA synthesis of herpes, vaccinica and varicella zoster viruses. However due to the discovery of new types of viruses and emergence of drug resistant strains, it is necessary to develop new antiviral lead compounds continuously. Several sponge derived antiviral lead compounds which are hopedto be developed as future drugs are discussed in this review. Supply problems are usually the major bottleneck to the development of these compounds as drugs during clinical trials. However advances in the field of metagenomics and high throughput microbial cultivation has raised the possibility that these techniques could lead to the cost-effective large scale production of such compounds. Perspectives on biotechnological methods with respect to marine drug development are also discussed.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1Marine sponges (phylum Porifera) are among the oldest multicellular invertebrate organisms exhibiting a wide variety of colors and shapes. About 8,000 species of sponges, inhabiting different marine and freshwater ecosystems have been described to date. Marine sponges are a rich source of potent natural products, some of which are considered as highly significant lead compounds for drug development. Most of these are secondary metabolites produced by the sponges which may be produced to defend themselves against pathogenic bacteria, algae, fungi and other potential predators; a system they have developed during the process of evolution throughout thousands of years. More than 5,300 different natural compounds have been discovered from sponges and their associated microorganisms, and every year several hundred new compounds are being added.

2Antiviral compounds are currently of particular interest since viral diseases (e.g., HIV, H1N1, HSV, etc.) have become major human health problems in recent decades. The ability of a virus to rapidly evolve and develop resistance to existing pharmaceuticals calls for continuing development of new antiviral drugs. Several lead antiviral compounds have been isolated from marine sponges, and there has been a consistent effort to identify new compounds.

3The nucleosides spongothymidine and spongouridine were the first compounds isolated from a marine sponge (Tethya crypta) which further led to the synthesis of Ara-C, an anticancer agent and Ara-A, the first antiviral drug. Ara-A inhibits viral DNA synthesis by conversion into adenine arabinoside triphosphate which inhibits viral DNA polymerase and DNA synthesis of herpes, vaccinica and varicella zoster viruses. It has been used clinically for treatment of herpes virus infection. Ara-A was the only sponge derived compound which was approved by the US FDA as an antiviral drug, although its marketing was later stopped as it was found to be less efficient and more toxic than the newer drug acyclovir (Zovirax). In addition to nucleosides, marine sponges are also the source of many alkaloids, sterols, terpenes, peptides, fatty acids, peroxides, etc. exhibiting the remarkable chemical diversity of compounds found in these organisms.

4Several other sponge derived antiviral compounds are in preclinical/clinical trials for various diseases. However significant problems associated with these compounds have been a major limitation in the drug development and approval process. This is primarily due to the many technological challenges in detecting, isolating, characterizing, and scaling up production of bioactive compounds from marine sponges. To solve the critical supply problem, several efforts are being made in sponge farming, metagenomics and microbial cultivation, which are discussed below. Here we focus on existing or promising antiviral lead compounds from marine sponges which may have the potential to be future drugs.

2.1.1. Vidarabine or Ara-A

5In 1950, Bergmann et al. isolated from the Caribbean sponge Tethya crypta (Tethylidae) the nucleosides spongothymidine and spongouridine, which contained an arabinose sugar rather than the more common ribose sugar found in these nucleosides. Vidarabine or Ara-A is a synthetic analogue of spongouridine with improved antiviral activity. The antiviral activity of adenine arabinoside (vidarabine, Ara-A, Figure 1) was first described by Privat de Garilhe and De Rudder in 1964. The work of Whitley in 1976 further confirmed the clinical usefulness of the compound in the treatment of herpes encephalitis and the other herpes infections that occasionally occur in newborns. It was the first nucleoside antiviral to be licensed for the treatment of systematic herpes virus infection and one of the three marine-derived drugs currently approved by the FDA in the United States, however the marketing of the drug has been discontinued because the availability of newer and better antiviral agents on the market.

6Despite its proven ability as a therapeutic agent which is active against a variety of viruses, vidarabine has some significant limitations. It is readily metabolized by adenosine deaminase (ADA) to arabinofuranosyl hypoxanthine (ara-H), which is 10-fold less potent and has low lipophilicity and thus low intestinal membrane permeability. It is also poorly soluble in aqueous solutions and has low intramuscular absorption, requires large fluid volumes for intravenous administration, and must be given over prolonged periods (8 to 12 h) to obtain therapeutic effects. Later acyclovir (Zovirax) was found to be a better drug than vidarabine for the treatment of herpes virus infections however vidarabine was reported to be capable of inhibiting acyclovir-resistant HSV and VZV (varicella-zoster virus). Vidarabine is an inhibitor of viral DNA synthesis. Adenine arabinoside (vidarabine) is converted into adenine arabinoside triphosphate (ara-ATP) in vivo by kinases encoded by viruses, which in turn inhibit viral DNA polymerase and hence DNA synthesis of herpes, vaccinia and varicella zoster viruses. Another study found that vidarabine is incorporated into RNA as well as DNA, leading to another possible mechanism of action of the drug. It was observed that vidarabine inhibited the initial RNA polyadenylation reaction catalyzed by chromatin-bound poly (A) polymerase. It was also recently reported that vidarabine was 3–5 fold more active in plaque reduction assays against vaccinia and cowpox viruses than was cidofovir (Vistide).

7Stereocontrolled synthesis of vidarabine and several analogues/derivatives with antiviral activity has been described. Its biosynthesis from Streptomyces antibioticus has also been reported.

2.1.2. Mycalamide A, Mycalamide B

8Perry et al. first reported the isolation and in vitro antiviral activity of mycalamide A and mycalamide B (Figure 2) from a New Zealand sponge of the genus Mycale in 1988 and 1990, respectively. The crude extract containing 2% mycalamide A was found to be active against A59 corona virus. After treatment with crude extract at 0.1 mg/kg, mice infected with virus survived for 14 days, however the mice infected with virus died within eight days. Mycalamide A also inhibited the Herpes simplex type I and Polio type I viruses at a concentration of 5 ng/disc. Mycalamide B was found to be more potent than mycalamide A, which was active at a concentration of 1–2 ng/disc. Examining the mechanisms involved in the actions of these compounds, Burres and Clement discovered the inhibition of protein synthesis and translation of RNA into protein in a cell-free lysate of rabbit reticulocytes. A new study also described the binding of mycalamide A to the E site of the large ribosomal subunit of Haloarcula marismortui and inhibition of protein synthesis. This property of protein synthesis inhibition may be attributed to their biological activity as antiviral agents.

9Several studies regarding the total synthesis of mycalamides have been published. Four analogues of mycalamide A have recently been reported to bind the nucleoprotein (NP) of influenza virus and inhibit its multiplication. It has also shown experimentally that these compounds might bind to the N-terminal 13-amino acid region of NP which mediates the nuclear transport of NP and its binding to viral RNA, and hence may inhibit viral replication.

Avarol

10Avarol, a sesquiterpenoid hydroquinone with a rearranged drimane skeleton, was first isolated from the marine sponge Disidea avara in 1974. The chemical structure of avarol (Figure 3) was established by standard analytical methods and chemical degradation and by its stereocontrolled total synthesis.

11The compound showed a dose-dependent inhibitory effect on the replication of the etiologic agent of acquired immune deficiency syndrome (AIDS) and human T-lymphotropic retrovirus (HTLV III)/lymphadenopathy-associated virus in human H9 cells in vitro at a concentration of 0.1 μg/mL. The study suggested that the mechanism involved blocking the expression of the p24 and p17 gag proteins of HTLV-III in H9 cells after virus infection, and hence blocking viral replication. Studies dating back to 1988 showed that the antiviral effects of avarol were due to an increase in intracellular levels of superoxide radicals such as superoxide dismutases and of glutathione peroxidase. The effects of avarol were further elucidated and it was found that it completely blocks the synthesis of glutamine transfer tRNA, which is crucial for synthesis of a viral protease required for viral proliferation. Other important biological targets inhibited by avarol or its derivatives include reverse transcriptase which plays a key role in early stages of viral infection, inhibition of cyclooxygenase and 5′-lipoxygenase, thus reducing the levels of leukotriene B4 and prostaglandin E2 in vitro in HIV-1 infected monocytes, and modulating the expression of genes in HIV-infected cells.

12The anti-viral activity of avarone, a structurally similar compound also from the marine sponge Disidea avara, and its derivatives has also been reported. Several new derivatives of avarol showing antiviral activities have also been extracted from the Red Sea sponge Dysidea cinerea. The first enantioselective total synthesis of avarol was reported by Ling et al.. In another attempt, the primmorph model (in vitro culture of sponge cells) was used as a model system to produce avarol in the laboratory. The cell culture and gene cluster approaches used for sustainable production of avarol have also been reviewed.

2.3.1. Papuamide A, B, C, and D

13The anti-HIV and cytotoxic cyclic depsipeptides, papuamides, were isolated from the sponges Theonella mirabilis and Theonella swinhoei that were collected along the north coast of Papua New Guinea. Two groups from the National Cancer Institute and the University of British Columbia independently reported the isolation of papuamides A and B from T. mirabilis and papuamides A, B, C, and D from T. swinhoei, respectively (Figure 4).

14Extensive NMR analysis confirmed the presence of different amino acid residues, including alanine, threonine, two glycine residues, homoproline, N-methylthreonine, 3-methoxyalanine, β-methoxytyrosine, 3-hydroxyleucine, 3,4-dimethylglutamine, 2,3-diaminobutanoic acid and an amide linked 2,3 dihydroxy-2,6,8-trimethyldeca-(4Z,6E)-dienoic acid. Papuamides A and B have been evaluated for their anti-HIV activity in cell based assays in CEM-SS T-cell cultures, and found to be highly potent with an effective concentration of3.6 ng/mL. Activities for both compounds were found to be virtually identical.

15Detailed mechanistic studies for the anti-HIV activity of papuamides A and B have been performed by Andjelic et al.. Inhibition of viral entry into cells is shown to be independent of CD4, gp120, chemokine co-receptors and gp41, key proteins which are involved in the process of viral entry and are the targets of most of the FDA approved inhibitors of this process. The mechanism of a direct interaction of papuamide A with the virus has been proposed witha membrane targeting mechanism believed to be responsible for the virucidal activity of the compound. A similar type of mechanism has been proposed for an antifungal sterol dependent lipopeptide. Papuamide B also inhibited viral entry at a concentration of 710 nM, with the proposed mechanism of targeting phosphatidylserine, a phospholipid present on the viral membrane. Papuamides C and D were found to be less potent with 30% and 55% inhibition at a concentration of 40 and 20 fold higher than papuamides A and B. In a recent study Xie et al. reported the total synthesis of papuamide B.

2.3.2. Microspinosamide

16Isolation of microspinosamide, a cyclic depsipeptide (Figure 5), from an Indonesian collection of the sponge Sidonops microspinosa was reported in 2001. Microspinosamide contained 13 amino acid residues including alanine, tryptophan, arginine, threonine, aspartate, valine, two prolines, tert-leucine, β-methylisoleucine, N-methylglutamine, cysteic acid and a new residue, β-hydroxy-p-bromo-phenylalanine. The Anti-HIV activity of crude extract of S. microspinosa was first discovered during the National Cancer Institute’s primary anti-HIV screening. Both aqueous and organic extracts of S. microspinosa exhibited anti-HIV activity. Microspinosamide was also evaluated for anti-HIV activity in a cell based in vitro assay and found to be effective at a concentration of 0.2 μg/mL in CEM-SS arget cells. Other cyclic depsipeptides from sponges with anti-HIV activity have also been reported.

2.4.1. 4-Methylaaptamine

17Isolation of the alkaloid 4-methylaaptamine (Figure 6) from the marine sponge Aaptos sp. (collected in Abrolhos, Bahia, Brazil) and the preliminary activity of its crude extract to inhibit 76% of HSV-1 replication in Vero cells at a concentration of 2.4 μg/mL was first reported by Coutinho et al.. Another study confirmed the anti-HSV-1 activity of 4-methylaaptamine with an EC50 of 2.4 μM, which is even more potent than acyclovir, which has an EC50 of 8.6 μM. 4-Methylaaptamine was found to inhibit HSV-1-infection in Vero cells even 4 h after infection, suggesting the inhibition of initial events during HSV-1 replication. Apparently the compound could inhibit expression of an HSV-1 immediate-early protein, ICP27, which regulates splicing, termination, and nuclear export of viral transcripts thus preventing viral replication.

18Synthetic transformation of methylaaptamine, which was first isolated by Nakamura and co-workers, into 4-methylaaptamine has also been reported. 9-O-4-Ethylbenzoylisoaaptamine, a novel derivative of isoaaptamine also displays potent activity against HIV-1 with an EC50 of 0.47 μg/mL.

2.4.2. Dragmacidin F

19Cutignano et al. reported the isolation of a new bromoindole alkaloid, dragmacidin F (Figure 7), from a marine sponge of the genus Halicortex collected off the southern coast of Ustica Island (Italy).

20The compound demonstrated in vitro antiviral activity against HSV-1 and HIV-1 with an EC50 of 96 μM and EC50 of 0.9 μM respectively and hence is most likely responsible for the antiviral property exhibited by Halicortex extracts. The compound has an unprecedented carbon skeleton that is presumed to be derived biosynthetically from dragmacidin D by the cyclization of its partially oxidized form. Total synthesis of (+)-dragmacidin F has been described by Garg et al..

2.4.3. Manzamine A

21Manzamine A (Figure 8) was isolated from Haliclona sp. Found in waters near Okinawa (Japan) by Sakai and Higa in their quest to find antitumor compounds from marine organisms. The manzamine class of alkaloids has unique complex polycyclic ring systems coupled with a β-carboline moiety and has been reported to have a diverse range of bioactivities, including antimicrobial, antiparasitic, antipesticidal, and anti-HIV-1 and activity against AIDS opportunistic infections. Isolation of manzamine A from the sponge Pachypellina sp. (Porifera, Demospongia, Petrosida, Oceanapiidae) collected at Manado Bay, Sulawesi, Indonesia has also been described. The same study reported the first anti HSV-II activity of this compound with a minimal effective concentration of 0.05 μg/mL. Isolation of manzamine A has also been reported from other species of marine sponges. Enantioselective total synthesis of manzamine A has been described by Humphrey et al..

22A more recent study describes the isolation of manzamine A from an undescribed sponge of the genusAcanthostrongylophora from Manado Bay, Indonesia; and its key oral and intravenous pharmacokinetic properties in rats have also been reported. This study, which was the first published information regarding the pharmacokinetic properties of manzamine A, indicated that the compound has a low metabolic clearance, a reasonably long pharmacokinetic half-life, and good absolute oral bioavailability, making it a promising potential lead for further preclinical assessment and possible development. This study also reported the anti-HIV-1 activity of manzamine A, 8-hydroxymanzamine A, 6-deoxymanzamine X, and neokauluamine with EC50 of 4.2, 0.6, 1.6, and 2.3 μM, respectively.

Hamigeran B

23This compound (Figure 9) was isolated from the marine sponge Hamigera tarangaensis (family Anchinoidae) from the Hen and Chicken Islands in New Zealand and showed 100% in vitro virus inhibition against both the herpes and polio virus with only slight cytotoxicity at a concentration of 132 μg per disk. Syntheses of hamigeran B have been reported by several groups 1.

3. Discussion

24A total of 40 compounds have been officially approved for clinical use in the treatment of various viral ailments and at least half of them are used for the treatment of HIV infection. Most of the sponge-derived compounds have also been screened for anti-HIV activity, showing the interest and potential importance of this field. This has led to the discovery of many compounds with anti-HIV activity, such as avarol, microspinosamide, papuamides A–D etc. Although many antiviral lead compounds have been derived from sponges, none of them has yet been approved as a drug (except Ara-A which is no longer in use). One of the reasons for this is the difficulty in obtaining a sustainable supply of these complex molecules for pre-clinical and clinical trials. Most of the pharmaceutically interesting compounds found in sponges are present in minute amounts. For example, in order to obtain even 300 mg of halichondrins, a potent cytostatic polyketide of sponge origin, 1 metric ton of the sponge Lissodendoryx sp. must be extracted. In addition, it is difficult to chemically synthesize most of these compounds due to their highly complex structures. In addition, the very long drug development process makes this problem even more challenging. It is clear that such a large amount of biomass of marine sponges cannot be harvested from nature, and in the event that it were it would put these species at risk of extinction. More environmentally friendly and economically feasible strategies are clearly needed. Mariculture of sponges for large scale production of these compounds is an option but insufficient knowledge of the conditions and specific parameters for the growth and cultivation of sponges in the laboratory are the limiting factors. Culturing cells and primmorphs for production of metabolites may be feasible in the future but at present this technique is unable to produce large amount of biomass.

25A growing body of evidence suggests that marine natural products may be the products of bacterial symbionts of sponges. The Faulkner group demonstrated for the first time that natural products from sponges could be of bacterial origin. Microorganisms associated with sponges have been characterized into 14 different phyla and their diversity and biotechnological importance have been reviewed. Isolation and cultivation of sponge-associated microorganisms (microbial fermentation) producing the bioactive natural products is also another option for the large scale production of compounds of interest. The success of this strategy depends on many factors. The majority of sponge associated microorganisms are difficult to culture. Improved culturing of sponge associated microorganisms by supplementing the media with sponge extract or catalase and sodium pyruvate has been reported, but the proportion of total cultured bacteria has remained low. Only 0.06 and 0.1% of total bacteria could be cultured from the sponges Candidaspongia flabellate and Rhopaloeides odorabile. Furthermore, microorganisms isolated from sponges may not necessarily produce the same compound due to the requirement of intermediate compound/s from the host. Some bacteria also stop producing the compound of interest after a certain time on artificial media, which may be caused by a number of genetic factors linked to lack of selective pressure in culture. To develop successful sponge culturing methods it is essential to understand the biology and natural living conditions of the sponges affecting growth and metabolite production. Various methods to culture sponges and sponge symbionts have been reviewed previously. The attempts to develop and grow in vitro cell lines from sponges from metabolite production have also been reported.

26Metagenomics is another strategy that has been used successfully to identify the biosynthetic origin of natural products. This procedure involves the genomic analysis of the total DNA in an organism and its symbionts. In the past few years metagenomics has emerged as a potential solution for genetic characterization of unculturable bacteria associated with marine sponges. The method involves direct extraction and cloning of DNA from a group of bacteria and its genomic sequencing. Initial efforts included the identification and isolation of gene clusters responsible for production of secondary metabolites involved in biosynthetic pathways, such as polyketide synthase (PKS) gene clusters. Another study reported the cloning of chondramide biosynthesis cluster from C. crocatus, a myxobacterium. The metagenomic approach was also employed for characterizing sponge-specific candidate phylum “Poribacteria” and a new molybdenum-containing oxidoreductase and transmembrane proteins were identified. The gene clusters identified using metagenomics approach is a step forward towards solving the problem of mass production of relevant natural products which further depends on the expression of the isolated gene clusters in relevant host. Heterologous expression vectors have been used to express the PKS biosynthetic clusters in Pseudomonas putida. Other examples of expression hosts include E. coli, Myxobacteria and Streptomyces used for expression of various biosynthetic pathways. Long et al. applied the expression based techniques to identify expressing clones. The isolation of compounds from marine metagenomes is successful to a limited extent but this technology has been effectively employed on soil metagenomes where several antibiotics have been isolated using metagenomic approaches. Although these studies demonstrate the success achieved by using the metagenomics approach there are still some technological issues related to this approach which must be overcome. Studies have provided compelling evidences that natural products known as polyketides are structurally similar in sponges and symbiont bacteria. It has been made clear that these bacteria are the key producers of polyketides. The complexity of the genomes of the group of organisms makes it very difficult to identify the target genome, and is further complicated by the use of inappropriate host organisms for cloning and expression as well as the large size of the gene clusters. The obstacles are manifold since sponges play host to a wide diversity of organisms such as bacteria, fungi, protists etc resulting in a complex community. The expression of such complex metagenome will not be feasible in simple expression systems such as E. coli. The complex expression systems are needed to achieve the success in case of sponges. To overcome the challenges associated with successful implementation of metagenomics approach, new methods have been developed and tested recently. One possible future direction could be to perform sequence based screens in order to identify enzymes that have been shown to be involved in the synthesis of anti-viral compounds. This strategy has been successfully developed and implicated to known polyketide synthase genes in an effort to identify new polyketides. Other recently developed phylogenetic approaches can be applied to study the structure and function of biosynthetic enzymes as well as to isolate target gene clusters. The metagenomic libraries can also be screened for antiviral activities by tailoring the methodologies previously used to identify natural-product clusters using genome sequence tags (GSTs). GSTs are the parts of the genes that can be used as probes to screen for similar genes in a clonal library. Any clone containing a GST can be a potential candidate for screening of novel natural-product gene clusters. This approach has been utilized to identify more than 450 natural-product clusters.

4. Conclusions

27The literature regarding antiviral compounds from sponges shows the significance of marine natural products in the drug discovery and development process. With advancement of technologies a new generation of potent and effective antiviral agents may be obtained from these sources. Sequence based screens, metagenomic clonal library screening using GSTs and other phylogenetic approaches could provide a new future dimension in search for antiviral natural compounds from sponges. The successes in metagenomics coupled with heterologous expression and high throughput microbial cultivation techniques could pave the way for commercial production of such compounds in the future, greatly facilitating their analysis and commercialization.

References 131

1.
Bergquist P SpongesUniv of California PressBerkeley, CA, USA1978
Not in our library
2.
Newman D Cragg G Marine natural products and related compounds in clinical and advanced preclinical trialsJ. Nat. Prod2004 6712161238
Not in our library10.1021/np040031y
3.
Sarma AS Daum T Miiller WEG Secondary Metabolites from Marine SpongesUllstein-Mosby VerlagBerlin, Germany1993
Not in our library
4.
Faulkner DJ Marine natural productsNat. Prod. Rep2002 19148
Not in our library10.1039/b009029h
5.
Bergmann W Feeney RJ The isolation of a new thymine pentoside from spongesJ. Am. Chem. Soc1950 7228092810
Not in our library
6.
Bergmann W Feeney RJ Contributions to the study of marine products. XXXII. The nucelosides of sponges. IJ. Org. Chem1951 16981987
Not in our library
7.
Shepp DH Dandliker PS Meyers JD Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabineN. Engl. J. Med1986 314208212
Not in our library10.1056/nejm198601233140404
8.
Whitley RJ Gnann JW Jr Hinthorn D Liu C Pollard RB Hayden F Mertz GJ Oxman M Soong SJ Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study GroupJ. Infect. Dis1992 165450455
Not in our library10.1093/infdis/165.3.450
9.
Blunt JW Copp BR Munro MH Northcote PT Prinsep MR Marine natural productsNat. Prod. Rep2005 221561
Not in our library10.1039/b415080p
10.
Privat de Garilhe M de Rudder J Effect of 2 arbinose nucleosides on the multiplication of herpes virus and vaccine in cell cultureC. R. Hebd. Seances Acad. Sci1964 25927252728
Not in our library
11.
Field H De Clercq E Antiviral drugs-a short history of their discovery and developmentMicrobiol. Today2004 315861
Not in our library
12.
Mayer AMS Glaser KB Cuevas C Jacobs RS Kem W Little RD McIntosh JM Newman DJ Potts BC Shuster DE The odyssey of marine pharmaceuticals: a current pipeline perspectiveTrends Pharmacol. Sci2010 316255265
Not in our library10.1016/j.tips.2010.02.005
13.
Shope TC Kauffman RE Bowman D Marcus EL Pharmacokinetics of vidarabine in the treatment of infants and children with infections due to herpesvirusesJ. Infect. Dis1983 148721725
Not in our library10.1093/infdis/148.4.721
14.
Sloan B Kielty J Miller F Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vira-Atm) for DNA virus replicationAnn. N.Y. Acad. Sci1977 28460
Not in our library10.1111/j.1749-6632.1977.tb21937.x
15.
Whitley R Tucker B Kinkel A Barton N Pass R Whelchel J Cobbs C Diethelm A Buchanan R Pharmacology, tolerance, and antiviral activity of vidarabine monophosphate in humansAntimicrob. Agents Chemother1980 18709
Not in our library10.1128/aac.18.5.709
16.
Kamiyama T Kurokawa M Shiraki K Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovirJ. Gen. Virol2001 8227612765
Not in our library10.1099/0022-1317-82-11-2761
17.
Shiraki K Namazue J Okuno T Yamanishi K Takahashi M Novel sensitivity of acyclovir-resistant varicella-zoster virus to anti-herpetic drugsAntiviral Chem. Chemother1990 1373375
Not in our library
18.
Doering A Keller J Cohen S Some effects of D-arabinosyl nucleosides on polymer syntheses in mouse fibroblastsCancer Res1966 262444
Not in our library
19.
Plunkett W Cohen SS Two approaches that increase the activity of analogs of adenine nucleosides in animal cellsCancer Res1975 3515471554
Not in our library
20.
Dicioccio RA Srivastava BI Kinetics of inhibition of deoxynucleotide-polymerizing enzyme activities from normal and leukemic human cells by 9-beta-d-arabinofuranosyladenine 5′-triphosphate and 1-beta-D-arabinofuranosylcytosine 5′-triphosphateEur. J. Biochem1977 79411418
Not in our library10.1111/j.1432-1033.1977.tb11823.x
21.
Rose K Jacob S Selective inhibition of RNA polyadenylation by Ara-ATP in vitro: a possible mechanism for antiviral action of Ara-ABiochem. Biophys. Res. Commun1978 8114181424
Not in our library10.1016/0006-291x(78)91294-9
22.
Hilfinger JMWZ Kim J Mitchell S Breitenbach J Amidon G Drach J Vidarabine Prodrugs as Anti-Pox Virus AgentsAntiviral Res2006 70A14
Not in our library
23.
Wang Z Prudhomme D Buck J Park M Rizzo C Stereocontrolled Syntheses of Deoxyribonucleosides via Photoinduced Electron-Transfer Deoxygenation of Benzoyl-Protected Ribo-and ArabinonucleosidesJ. Org. Chem2000 6559695985
Not in our library10.1021/jo0003652
24.
Darzynkiewicz E Kazimierczuk Z Shugar D Preparation and properties of the O-methyl derivatives of 9-beta-D-arabinofuranosyladenineCancer Biochem. Biophys1976 1203209
Not in our library
25.
Kotra L Manouilov K Cretton-Scott E Sommadossi J Boudinot F Schinazi R Chu C Synthesis, biotransformation, and pharmacokinetic studies of 9-(D-arabinofuranosyl)-6-azidopurine: A prodrug for Ara-A designed to utilize the azide reduction pathwayJ. Med. Chem1996 3952025207
Not in our library10.1021/jm960339p
26.
McGuigan C Shackleton J Tollerfield S Riley P Synthesis and evaluation of some novel phosphate and phosphinate derivatives of araA. Studies on the mechanism of action of phosphate triestersNucleic Acids Res1989 171017110177
Not in our library10.1093/nar/17.24.10171
27.
Suhadolnik R Pornbanlualap S Wu J Baker D Hebbler A Biosynthesis of 9-[beta]-arabinofuranosyladenine: Hydrogen exchange at C-2′and oxygen exchange at C-3′of adenosine* 1Arch. Biochem. Biophys1989 270363373
Not in our library10.1016/0003-9861(89)90039-8
28.
Perry N Blunt J Munro M Pannell L Mycalamide A, an antiviral compound from a New Zealand sponge of the genus MycaleJ. Am. Chem. Soc1988 11048504851
Not in our library
29.
Perry NB Blunt JW Munro MHG Thompson AM Antiviral and antitumor agents from a New Zealand sponge, Mycale sp. 2. Structures and solution conformations of mycalamides A and BJ. Org. Chem1990 55223227
Not in our library
30.
Burres N Clement J Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and-B and onnamideCancer Res1989 492935
Not in our library
31.
Gurel G Blaha G Steitz T Moore P The structures of Triacetyloleandomycin and Mycalamide A bound to the large ribosomal subunit of Haloarcula marismortuiAntimicrob. Agents Chemother2009 5350105014
Not in our library10.1128/aac.00817-09
32.
Kagawa N Ihara M Toyota M Total Synthesis of (+)-Mycalamide AOrg. Lett2006 8875878
Not in our library10.1021/ol052943c
33.
Sohn J Waizumi N Zhong H Rawal V Total synthesis of mycalamide AJ. Am. Chem. Soc2005 12772907291
Not in our library10.1021/ja050728l
34.
Toyota M Hirota M Hirano H Ihara M A stereoselective synthesis of the C-10 to C-18 (right-half) fragment of mycalamides employing lewis acid promoted intermolecular aldol reactionOrg. Lett2000 220312034
Not in our library10.1021/ol000072v
35.
Trost B Yang H Probst G A formal synthesis of (−)-mycalamide AJ. Am. Chem. Soc2004 1264849
Not in our library10.1021/ja038787r
36.
Hagiwara K Kondoh Y Ueda A Yamada K Goto H Watanabe T Nakata T Osada H Aida Y Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arraysBiochem. Biophys. Res. Commun2010 3943721727
Not in our library10.1016/j.bbrc.2010.03.058
37.
Minale L Riccio R Sodano G Avarol a novel sesquiterpenoid hydroquinone with a rearranged drimane skeleton from the spongeTetrahedron Lett1974 1534013404
Not in our library
38.
Rosa S Minale L Riccio R Sodano G The absolute configuration of avarol, a rearranged sesquiterpenoid hydroquinone from a marine spongeJ. Chem. Soc. Perkin Trans. 11976 197614081414
Not in our library
39.
Sarma A Chattopadhyay P Synthetic studies of trans-clerodane diterpenoids and congeners: stereocontrolled total synthesis of (±)-avarolJ. Org. Chem1982 4717271731
Not in our library
40.
Sarin P Sun D Thornton A Muller W Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avaroneJ. Natl. Cancer Inst1987 78663666
Not in our library
41.
Batke E Ogura R Vaupel P Hummel K Kallinowski F Gasić MJ Schröder H Müllerm W Action of the antileukemic and anti-HTLV-III (anti-HIV) agent avarol on the levels of superoxide dismutases and glutathione peroxidase activities in L5178y mouse lymphoma cellsCell Biochem. Funct1988 6123129
Not in our library10.1002/cbf.290060207
42.
Kuchino Y Nishimura S Schröder H Rottmann M Müller W Selective inhibition of formation of suppressor glutamine tRNA in Moloney murine leukemia virus-infected NIH-3T3 cells by AvarolVirology1988 165518526
Not in our library10.1016/0042-6822(88)90596-x
43.
Muller W Schroder H Cell biological aspects of HIV-1 infection: effects of the anti-HIV-1 agent avarolInt. J. Sports Med1991 12S4349
Not in our library10.1055/s-2007-1024749
44.
Muller WE Schroder HC Reuter P Sarin PS Hess G Meyer zum Buschenfelde KH Kuchino Y Nishimura S Inhibition of expression of natural UAG suppressor glutamine tRNA in HIV-infected human H9 cells in vitro by AvarolAIDS Res. Hum. Retroviruses1988 4279286
Not in our library10.1089/aid.1988.4.279
45.
Loya S Hizi A The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivativesFEBS Lett1990 269131134
Not in our library10.1016/0014-5793(90)81137-d
46.
Schröder H Bégin M Klöcking R Matthes E Sarma A Gašić M Müller W Avarol restores the altered prostaglandin and leukotriene metabolism in monocytes infected with human immunodeficiency virus type 1Virus Res1991 21213223
Not in our library10.1016/0168-1702(91)90034-s
47.
Sarin P Sun D Thornton A Miller W Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avaroneJ. Natl. Cancer Inst1987 78663
Not in our library
48.
De Giulio A De Rosa S Strazzulo G Diliberto L Obino P Marongiu ME Pani A La Colla P Synthesis and evaluation of cytostatic and antiviral activities of 3′and 4′-avarone derivativesAntiviral Chem. Chemother1991 2223227
Not in our library
49.
Suhadolnik R Pornbanlualap S Baker D Tiwari K Hebbler A Stereospecific 2′-amination and 2′-chlorination of adenosine by Actinomadura in the biosynthesis of 2′-amino-2′-deoxyadenosine and 2′-chloro-2′-deoxycoformycin* 1Arch. Biochem. Biophys1989 270374382
Not in our library10.1016/0003-9861(89)90040-4
50.
Ling T Xiang A Theodorakis E Enantioselective total synthesis of avarol and avaroneAngew. Chem. Int. Ed1999 3830893091
Not in our library10.1002/(sici)1521-3773(19991018)38:20<3089::aid-anie3089>3.0.co;2-w
51.
Muller W Bohm M Batel R De Rosa S Tommonaro G Muller I Schroder H Application of cell culture for the production of bioactive compounds from sponges: synthesis of avarol by primmorphs from Dysidea avaraJ. Nat. Prod2000 6310771081
Not in our library10.1021/np000003p
52.
Müller W Grebenjuk V Le Pennec G Schröder H Brümmer F Hentschel U Müller I Breter H Sustainable production of bioactive compounds by sponges—cell culture and gene cluster approach: a reviewMar. Biotechnol2004 6105117
Not in our library10.1007/s10126-002-0098-6
53.
Ford P Gustafson K McKee T Shigematsu N Maurizi L Pannell L Williams D de Silva E Lassota P Allen T Papuamides A–D, HIV-Inhibitory and Cytotoxic Depsipeptides from the Sponges Theonella mirabilis and Theonella swinhoei Collected in Papua New GuineaJ. Am. Chem. Soc1999 12158995909
Not in our library
54.
Xie W Ding D Zi W Li G Ma D Total Synthesis and Structure Assignment of Papuamide B, A Potent Marine Cyclodepsipeptide with Anti-HIV Properties13Angew. Chem. Int. Ed2008 4728442848
Not in our library10.1002/anie.200705557
55.
Andjelic C Planelles V Barrows L Characterizing the Anti-HIV Activity of Papuamide AMar. Drugs2008 6528549
Not in our library10.3390/md20080027
56.
Esté J Telenti A HIV entry inhibitorsLancet2007 3708188
Not in our library10.1016/s0140-6736(07)61052-6
57.
Volpon L Besson F Lancelin J NMR structure of active and inactive forms of the sterol-dependent antifungal antibiotic bacillomycin LEur. J. Biochem2001 264200210
Not in our library10.1046/j.1432-1327.1999.00605.x
58.
Rashid M Gustafson K Cartner L Shigematsu N Pannell L Boyd M Microspinosamide, a new HIV-inhibitory cyclic depsipeptide from the marine sponge Sidonops microspinosa1J. Nat. Prod2001 64117121
Not in our library10.1021/np0002379
59.
Boyd M De Vita VT Jr Hellman S Rosenberg SA AIDS Etiology, Diagnosis, Treatment and PreventionLippincott Williams & WilkinsPhiladelphia, PA, USA1988 305319
Not in our library
60.
Valeria D’Auria M Zampella A Paloma LG Minale L Debitus C Roussakis C Le Bert V Callipeltins B and C; bioactive peptides from a marine Lithistida sponge Callipelta spTetrahedron1996 5295899596
Not in our library
61.
Zampella A D’Auria M Paloma L Casapullo A Minale L Debitus C Henin Y Callipeltin A, an anti-HIV cyclic depsipeptide from the New Caledonian Lithistida sponge Callipelta spJ. Am. Chem. Soc1996 11862026209
Not in our library
62.
Coutinho AF Chanas B e Souza TML Frugrulhetti ICPP de A Epifanio R Anti HSV-1 alkaloids from a feeding deterrent marine sponge of the genus AaptosHeterocycles2002 5712651272
Not in our library
63.
Souza T Abrantes J de A Epifanio R Fontes C Frugulhetti I The Alkaloid 4-Methylaaptamine Isolated from the Sponge Aaptos aaptos Impairs Herpes simplex Virus Type 1 Penetration and Immediate-Early Protein SynthesisPlanta Med2007 73200205
Not in our library10.1055/s-2007-967109
64.
Nakamura H Kobayashi J Ohizumi Yoshimasa Y Isolation and structure of aaptamine a novel heteroaromatic substance possessing [alpha]-blocking activity from the sea spongeTetrahedron Lett1982 2355555558
Not in our library
65.
Pettit G Hoffmann H Herald D McNulty J Murphy A Higgs K Hamel E Lewin N Pearce L Blumberg P Antineoplastic agents 491. Synthetic conversion of aaptamine to isoaaptamine, 9-demethylaaptamine, and 4-methylaaptamineJ. Org. Chem2004 6922512256
Not in our library10.1021/jo0300486
66.
Gul W Hammond N Yousaf M Bowling J Schinazi R Wirtz S de Castro Andrews G Cuevas C Hamann M Modification at the C9 position of the marine natural product isoaaptamine and the impact on HIV-1, mycobacterial, and tumor cell activityBioorg. Med. Chem2006 1484958505
Not in our library10.1016/j.bmc.2006.08.042
67.
Cutignano A Bifulco G Bruno I Casapullo A Gomez-Paloma L Riccio R Dragmacidin F: A New Antiviral Bromoindole Alkaloid from the Mediterranean Sponge Halicortex spTetrahedron2000 5637433748
Not in our library
68.
Garg N Caspi D Stoltz B The total synthesis of (+)-dragmacidin FJ. Am. Chem. Soc2004 12695529553
Not in our library10.1021/ja046695b
69.
Sakai R Higa T Jefford CW Bernardinelli G Manzamine A, a novel antitumor alkaloid from a spongeJ. Am. Chem. Soc1986 10864046405
Not in our library
70.
El Sayed KA Kelly M Kara UAK Ang KKH Katsuyama I Dunbar DC Khan AA Hamann MT New Manzamine Alkaloids with Potent Activity against Infectious DiseasesJ. Am. Chem. Soc2001 12318041808
Not in our library10.1021/ja002073o
71.
Rao KV Santarsiero BD Mesecar AD Schinazi RF Tekwani BL Hamann MT New Manzamine Alkaloids with Activity against Infectious and Tropical Parasitic Diseases from an Indonesian SpongeJ. Nat. Prod2003 66823828
Not in our library10.1021/np020592u
72.
Ang K Holmes M Higa T Hamann M Kara U In vivo antimalarial activity of the betacarboline alkaloid manzamine AAntimicrob. Agents Chemother2000 441645
Not in our library10.1128/aac.44.6.1645-1649.2000
73.
Peng J Shen X El Sayed K Dunbar D Perry T Wilkins S Hamann M Bobzin S Huesing J Camp R Marine natural products as prototype agrochemical agentsJ. Agric. Food Chem2003 5122462252
Not in our library10.1021/jf0207880
74.
Peng J Rao K Choo Y Hamann M Fattorusso E Taglialatela-Scafati O Manzamine AlkaloidsModern Alkaloids: Structure, Isolation, Synthesis and BiologyWileyWeinheim, Germany2007 189231
Not in our library
75.
Ichiba T Corgiat J Scheuer P Kelly-Borges M 8-Hydroxymanzamine A, a beta-carboline alkaloid from a sponge, Pachypellina spJ. Nat. Prod1994 57168170
Not in our library10.1021/np50103a027
76.
Edrada R Proksch P Wray V Witte L Muller W van Soest R Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmoricaJ. Nat. Prod1996 5910561060
Not in our library10.1021/np9604083
77.
Rao K Santarsiero B Mesecar A Schinazi R Tekwani B Hamann M New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian spongeJ. Nat. Prod2003 66823828
Not in our library10.1021/np020592u
78.
Samoylenko V Khan S Jacob M Tekwani B Walker L Hufford C Muhammad I Bioactive (+)-Manzamine A and (+)-Hydroxymanzamine A Tertiary Bases and Salts from Acanthostrongylophora ingens and Their PreparationsNat. Prod. Commun2009 4185192
Not in our library
79.
Humphrey J Liao Y Ali A Rein T Wong Y Chen H Courtney A Martin S Enantioselective total syntheses of manzamine A and related alkaloidsJ. Am. Chem. Soc2002 12485848592
Not in our library10.1021/ja0202964
80.
Yousaf M Hammond N Peng J Wahyuono S McIntosh K Charman W Mayer A Hamann M New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseasesJ. Med. Chem2004 4735123517
Not in our library10.1021/jm030475b
81.
Clive DLJ Wang J Stereospecific Total Synthesis of the Antiviral Agent Hamigeran B - Use of Large Silyl Groups to Enforce Facial Selectivity and to Suppress Hydrogenolysis13Angew. Chem. Int. Ed2003 4234063409
Not in our library10.1002/anie.200351519
82.
Trost B Pissot-Soldermann C Chen I Schroeder G An asymmetric synthesis of hamigeran B via a Pd asymmetric allylic alkylation for enantiodiscriminationJ. Am. Chem. Soc2004 12644804481
Not in our library10.1021/ja0497025
83.
Trost BM Pissot-Soldermann C Chen I A short and concise asymmetric synthesis of hamigeran BChemistry2005 11951959
Not in our library10.1002/chem.200400558
84.
da Silva A Kratz J Farias F Henriques A dos SANTOS J Leonel R Lerner C Mothes B Barardi C Simões C In vitro antiviral activity of marine sponges collected off Brazilian coastBiol. Pharm. Bull2006 29135140
Not in our library10.1248/bpb.29.135
85.
Proksch P Edrada R Ebel R Drugs from the seas-current status and microbiological implicationsAppl. Microbiol. Biotechnol2002 59125134
Not in our library10.1007/s00253-002-1006-8
86.
Hart J Lill R Hickford S Blunt J Munro M The halichondrins: chemistry, biology, supply and deliveryDrugs Sea2000 134153
Not in our library
87.
Wall M Wani M Camptothecin and taxol: discovery to clinic—thirteenth Bruce F. Cain Memorial Award LectureCancer Res1995 55753760
Not in our library
88.
Belarbi E Gómez C Producing drugs from marine spongesBiotechnol. Adv2003 21585598
Not in our library10.1016/s0734-9750(03)00100-9
89.
Flowers A Garson M Webb R Dumdei E Charan R Cellular origin of chlorinated diketopiperazines in the dictyoceratid sponge Dysidea herbacea (Keller)Cell Tissue Res1998 292597607
Not in our library10.1007/s004410051089
90.
Ridley C Bergquist P Harper M Faulkner D Hooper J Haygood M Speciation and biosynthetic variation in four dictyoceratid sponges and their cyanobacterial symbiont, Oscillatoria spongeliaeChem. Biol2005 12397406
Not in our library10.1016/j.chembiol.2005.02.003
91.
Unson M Holland N Faulkner D A brominated secondary metabolite synthesized by the cyanobacterial symbiont of a marine sponge and accumulation of the crystalline metabolite in the sponge tissueMar. Biol1994 119111
Not in our library
92.
Taylor M Radax R Steger D Wagner M Sponge-associated microorganisms: evolution, ecology, and biotechnological potentialMicrobiol. Mol. Biol. Rev2007 71295
Not in our library10.1128/mmbr.00040-06
93.
Dieckmann R Graeber I Kaesler I Szewzyk U von Doehren H Rapid screening and dereplication of bacterial isolates from marine sponges of the Sula Ridge by intact-cell-MALDI-TOF mass spectrometry (ICM-MS)Appl. Microbiol. Biotechnol2005 67539548
Not in our library10.1007/s00253-004-1812-2
94.
Gunasekera A Sfanos K Harmody D Pomponi S McCarthy P Lopez J HBMMD: an enhanced database of the microorganisms associated with deeper water marine invertebratesAppl. Microbiol. Biotechnol2005 66373376
Not in our library10.1007/s00253-004-1763-7
95.
Staley J Konopka A Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitatsAnnu. Rev. Microbiol1985 39321346
Not in our library10.1146/annurev.mi.39.100185.001541
96.
Webster N Hill R The culturable microbial community of the Great Barrier Reef sponge Rhopaloeides odorabile is dominated by an -ProteobacteriumMar. Biol2001 138843851
Not in our library
97.
Webster N Wilson K Blackall L Hill R Phylogenetic diversity of bacteria associated with the marine sponge Rhopaloeides odorabileAppl. Environ. Microbiol2001 67434
Not in our library10.1128/aem.67.1.434-444.2001
98.
Olson J Lord C McCarthy P Improved recoverability of microbial colonies from marine sponge samplesMicrob. Ecol2000 40139147
Not in our library10.1007/s002480000058
99.
Burja A Webster N Murphy P Hill R Microbial symbionts of Great Barrier Reef spongesMem. Queensl. Mus1999 446376
Not in our library
100.
Taylor M Radax R Steger D Wagner M Sponge-associated microorganisms: evolution, ecology, and biotechnological potentialMicrobiol. Mol. Biol. Rev2007 71295307
Not in our library10.1128/mmbr.00040-06
101.
Duckworth A Farming Sponges to Supply Bioactive Metabolites and Bath Sponges: A ReviewMar. Biotechnol2009 11669679
Not in our library10.1007/s10126-009-9213-2
102.
Koopmans M Martens D Wijffels R Towards Commercial Production of Sponge MedicinesMar. Drugs2009 7787802
Not in our library10.3390/md7040787
103.
Wijffels R Potential of sponges and microalgae for marine biotechnologyTrends Biotechnol2008 262631
Not in our library10.1016/j.tibtech.2007.10.002
104.
Kennedy J Marchesi J Dobson A Metagenomic approaches to exploit the biotechnological potential of the microbial consortia of marine spongesAppl. Microbiol. Biotechnol2007 751120
Not in our library10.1007/s00253-007-0875-2
105.
Handelsman J Metagenomics: Application of Genomics to Uncultured MicroorganismsMicrobiol. Mol. Biol. Rev2004 68669685
Not in our library10.1128/mmbr.68.4.669-685.2004
106.
Kim TK Fuerst JA Diversity of polyketide synthase genes from bacteria associated with the marine sponge Pseudoceratina clavata: culture-dependent and culture-independent approachesEnviron. Microbiol2006 814601470
Not in our library10.1111/j.1462-2920.2006.01040.x
107.
Schirmer A Gadkari R Reeves CD Ibrahim F DeLong EF Hutchinson CR Metagenomic Analysis Reveals Diverse Polyketide Synthase Gene Clusters in Microorganisms Associated with the Marine Sponge Discodermia dissolutaAppl. Environ. Microbiol2005 7148404849
Not in our library10.1128/aem.71.8.4840-4849.2005
108.
Rachid S Krug D Kunze B Kochems I Scharfe M Zabriskie TM Blöcker H Müller R Molecular and Biochemical Studies of Chondramide Formation--Highly Cytotoxic Natural Products from Chondromyces crocatus Cm c5Chem. Biol2006 13667681
Not in our library10.1016/j.chembiol.2006.06.002
109.
Fieseler L Horn M Wagner M Hentschel U Discovery of the Novel Candidate Phylum “Poribacteria” in Marine SpongesAppl. Environ. Microbiol2004 7037243732
Not in our library10.1128/aem.70.6.3724-3732.2004
110.
Fieseler L Quaiser A Schleper C Hentschel U Analysis of the first genome fragment from the marine sponge-associated, novel candidate phylum Poribacteria by environmental genomicsEnviron. Microbiol2006 8612624
Not in our library10.1111/j.1462-2920.2005.00937.x
111.
Gross F Ring M Perlova O Fu J Schneider S Gerth K Kuhlmann S Stewart A Zhang Y Müller R Metabolic engineering of Pseudomonas putida for methylmalonyl-CoA biosynthesis to enable complex heterologous secondary metabolite formationChem. Biol2006 1312531264
Not in our library10.1016/j.chembiol.2006.09.014
112.
Wenzel S Gross F Zhang Y Fu J Stewart A Müller R Heterologous expression of a myxobacterial natural products assembly line in pseudomonads via red/ET recombineeringChem. Biol2005 12349356
Not in our library10.1016/j.chembiol.2004.12.012
113.
Khosla C Keasling J Metabolic engineering for drug discovery and developmentNat. Rev. Drug Discov2003 210191025
Not in our library10.1038/nrd1256
114.
Mutka S Carney J Liu Y Kennedy J Heterologous Production of Epothilone C and D in Escherichia coliBiochemistry2006 4513211330
Not in our library10.1021/bi052075r
115.
Newman J Marshall J Chang M Nowroozi F Paradise E Pitera D Newman K Keasling J High-level production of amorpha-4, 11-diene in a two-phase partitioning bioreactor of metabolically engineered Escherichia coliBiotechnol. Bioeng2006 95684691
Not in our library10.1002/bit.21017
116.
Julien B Shah S Heterologous expression of epothilone biosynthetic genes in Myxococcus xanthusAntimicrob. Agents Chemother2002 462772
Not in our library10.1128/aac.46.9.2772-2778.2002
117.
Pfeifer B Khosla C Biosynthesis of polyketides in heterologous hostsMicrobiol. Mol. Biol. Rev2001 65106
Not in our library10.1128/mmbr.65.1.106-118.2001
118.
Long P Dunlap W Battershill C Jaspars M Shotgun cloning and heterologous expression of the patellamide gene cluster as a strategy to achieving sustained metabolite productionChemBioChem2005 617601765
Not in our library10.1002/cbic.200500210
119.
Brady S Chao C Clardy J New natural product families from an environmental DNA (eDNA) gene clusterJ. Am. Chem. Soc2002 12499689969
Not in our library10.1021/ja0268985
120.
Brady S Chao C Handelsman J Clardy J Cloning and heterologous expression of a natural product biosynthetic gene cluster from eDNAOrg. Lett2001 319811984
Not in our library10.1021/ol015949k
121.
Gillespie D Brady S Bettermann A Cianciotto N Liles M Rondon M Clardy J Goodman R Handelsman J Isolation of antibiotics turbomycin A and B from a metagenomic library of soil microbial DNAAppl. Environ. Microbiol2002 684301
Not in our library10.1128/aem.68.9.4301-4306.2002
122.
MacNeil I Tiong C Minor C August P Grossman T Loiacono K Lynch B Phillips T Narula S Sundaramoorthi R Expression and isolation of antimicrobial small molecules from soil DNA librariesJ. Mol. Microbiol. Biotechnol2001 3301308
Not in our library
123.
Sipkema D Franssen M Osinga R Tramper J Wijffels R Marine sponges as pharmacyMar. Biotechnol2005 7142162
Not in our library10.1007/s10126-004-0405-5
124.
Piel J Hui D Wen G Butzke D Platzer M Fusetani N Matsunaga S Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoeiProc. Natl. Acad. Sci. USA2004 10116222
Not in our library10.1073/pnas.0405976101
125.
Sudek S Lopanik N Waggoner L Hildebrand M Anderson C Liu H Patel A Sherman D Haygood M Identification of the putative bryostatin polyketide synthase gene cluster from “Candidatus Endobugula sertula”, the uncultivated microbial symbiont of the marine bryozoan Bugula neritinaJ. Nat. Prod2007 706774
Not in our library10.1021/np060361d
126.
Fortman JL Sherman DH Utilizing the Power of Microbial Genetics to Bridge the Gap Between the Promise and the Application of Marine Natural ProductsChemBioChem2005 6960978
Not in our library10.1002/cbic.200400428
127.
Taylor MW Radax R Steger D Wagner M Sponge-Associated Microorganisms: Evolution, Ecology, and Biotechnological PotentialMicrobiol. Mol. Biol. Rev2007 71295347
Not in our library10.1128/mmbr.00040-06
128.
Wang G Diversity and biotechnological potential of the sponge-associated microbial consortiaJ. Ind. Microbiol. Biotechnol2006 33545551
Not in our library10.1007/s10295-006-0123-2
129.
Fisch K Gurgui C Heycke N van der Sar S Anderson S Webb V Taudien S Platzer M Rubio B Robinson S Polyketide assembly lines of uncultivated sponge symbionts from structure-based gene targetingNat. Chem. Biol2009 5494501
Not in our library10.1038/nchembio.176
130.
Hochmuth T Piel J Polyketide synthases of bacterial symbionts in sponges-Evolution-based applications in natural products researchPhytochemistry2009 7018411849
Not in our library10.1016/j.phytochem.2009.04.010
131.
Zhang L An R Wang J Sun N Zhang S Hu J Kuai J Exploring novel bioactive compounds from marine microbesCurr. Opin. Microbiol2005 8276281
Not in our library10.1016/j.mib.2005.04.008

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.